Introduction
============

Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders with over 16% of adults in the US experiencing a depressive event within their lifetime, and over half of these events leading to severe or very severe role impairment ([@B60]; [@B43]). While a multitude of antidepressant drugs are now available, no one treatment is fully effective in all patients, with about one third failing to remit even after 4th line treatments ([@B58]). This high rate of treatment failure combined with the high prevalence of depressive disorders highlights the need not only for improved treatment options, but also for a better understanding of the molecular and cellular factors that determine whether a given treatment will succeed or fail.

In this review we highlight the role of G-proteins and their signaling partners, especially the Regulators of G-protein Signaling (RGS) proteins, in both the etiology and treatment of depression.

GPCRS in Depression
===================

The vast majority of drugs prescribed for depressive disorders either interact directly with G-protein coupled receptors (GPCRs), e.g., buspirone with the 5-HT1A receptor or aripiprazole with a multitude of monoaminergic GPCRs, or indirectly regulate GPCR function by affecting endogenous neurotransmitter levels, e.g., selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and monoamine oxidase inhibitors (MAOIs) such as selegiline ([@B59]).

G-protein coupled receptors are 7-transmembrane domain proteins that form a multi-protein complex with members of an intracellular family of heterotrimeric G-proteins comprised of a Gα subunit and a βγ dimer (Figure [1](#F1){ref-type="fig"}). There are several members of the Gα family that couple to different cohorts of effectors in the cell. These include the so-called inhibitory Gα proteins (Gα~i/o~ and Gα~z~), which inhibit adenylyl cyclase to decrease cyclic adenosine monophosphate (cAMP), the adenylyl cyclase stimulatory Gα~s~ and Gα~olf~, Gα~q~ which activates phospholipase C, and Gα~12/13~ that couple to the Rho family of small GTPases. There are 5 β subunits and 11 γ subunits that can be engaged to make the associated βγ dimer in mammals. There is selectivity of receptors for particular types of Gα proteins, and also for activation or inhibition of downstream effectors in the cell. Following GPCR activation by endogenous neurotransmitters or exogenous agonists both the Gα subunit and the Gβγ complex functionally dissociate from the receptor and go on to stimulate or inhibit a range of intracellular effectors. The Gα activation process involves a loss of bound GDP (inactive form) in exchange for GTP (active form). Signaling is terminated by the hydrolysis of the bound GTP back to GDP by the intrinsic GTPase activity of the Gα subunit. However, for certain Gα proteins this enzymatic process is slow. To accelerate this process a [r]{.ul}egulator of [G]{.ul}-protein [s]{.ul}ignaling (RGS) protein binds to the active GTP-bound Gα and facilitates its inactivation, acting as a GAP ([G]{.ul}TPase [a]{.ul}ccelerating [p]{.ul}rotein; Figure [1](#F1){ref-type="fig"}). This allows return to the resting, inactive state. The inactive GDP-bound Gα subunit can then recouple with both the Gβγ complex and receptor until the receptor is again activated and the cycle repeats. Although RGS proteins can substantially limit Gα~i/o~ and Gα~q~ signaling (see [@B89] for review) their impact on Gα~s~ mediated signaling is less pronounced. While an RGS for Gα~s~ has been identified, it is not clear that this protein facilitates the GTPase activity of Gα~s~ ([@B131]; [@B46]).

![Heterotrimeric G-protein signaling with RGS regulation. GPCR activation, either due to agonist binding or constitutive activity, causes downstream signaling through both the α and βγ subunits. Various antidepressants modulate this process directly (e.g., Buspirone) or indirectly (e.g., SSRIs). RGS proteins interact with active Gα and accelerate its GTPase activity, facilitating a return to the GDP-bound inactive state. Preclinical models suggest that direct manipulation of the RGS or G-proteins can affect antidepressant response.](fphar-09-01289-g001){#F1}

In addition to mediating the actions of antidepressant drugs, many GPCRs have been associated with the development of depression. Aberrations in both α- and β-adrenergic receptor signaling have been found in depressed patients ([@B79]; [@B36]) and the brains of suicide victims consistently have alterations in 5-HT1A receptor expression (and various nuclear receptors) resembling the alterations produced by chronic stress in animal models ([@B72]). In contrast, study of 5-HT2A and 5-HT2C receptor expression levels has produced inconsistent results (see [@B114] for review). Nonetheless, a 5-HT2C receptor polymorphism in the N-terminal extracellular domain has been associated with MDD in a large population study ([@B67]). Preclinical models also implicate the 5-HT1B receptor both in the genesis of depressive states and in antidepressant action ([@B117]). Polymorphisms in both the dopamine D3 and D4 receptors have been correlated with the development of MDD ([@B26]; [@B73]), while D1 and D2 receptors have instead been linked to bipolar disorder ([@B77]; [@B27]). Interestingly the GABA-B receptor agonist baclofen produces a transient depressive state in some patients ([@B99]), suggesting this receptor may play a role in MDD. A corticotropin-releasing hormone receptor 1 antagonist has also been found to have antidepressant activity ([@B133]), in agreement with predictions from preclinical studies ([@B76]).

Downstream signaling bias is also affected by proteins in complex with the receptor. For example, the 5-HT1A receptor can form receptor/receptor complexes with the 5-HT7 receptor, the ghrelin receptor family member GPR39, or fibroblast growth factor receptor 1 (FGFR1), with each heterodimer complex producing a unique downstream signaling profile ([@B101]; [@B121]; [@B11]). The 5-HT1A/5-HT7 heterodimer complex promotes internalization of the 5-HT1A receptor ([@B101]), suggesting that the high degree of colocalization between these receptors in the dorsal raphe nucleus may contribute to 5-HT1A autoreceptor desensitization observed during SSRI treatment ([@B87]). These results imply that strategies which promote 5-HT1A/5-HT7 heterodimer formation could facilitate the antidepressant effects of SSRIs by attenuating 5-HT1A autoreceptor activity. In contrast, combined 5-HT1A receptor and FGFR1 agonist treatment fails to produce antidepressant-like behavior in rats with low hippocampal 5-HT1A/FGFR1 heterodimer expression ([@B11]), while these agonists produce robust antidepressant-like effects in rats with increased dimer formation. These heterodimer dependent behavioral effects are likely mediated by a reduced ability of the 5-HT1A/FRGR1 heterodimer to activate G-protein coupled inwardly rectifying potassium (GIRK) channels, compared to the free 5-HT1A receptor ([@B11]). These results suggest that 5-HT1A receptor stimulated GIRK activity in the hippocampus is in fact detrimental to antidepressant activity, and that agonists which preferentially couple to 5-HT1A/FGFR1 heterodimers would be superior to unbiased ligands. For a recent review on how GPCR oligomerization can affect receptor activity, see [@B118] and [@B40] for review of GPCR heterodimers in depression.

The above discussion suggests that insight into the roles of specific G-proteins and their cognate RGS proteins in antidepressant action may facilitate future antidepressant drug development. Furthermore, studying dysfunction of these systems in the depressed brain may provide insight into the etiology of depression.

G-Protein Subunits in Depression and Antidepressant Action
==========================================================

G-protein Expression Levels
---------------------------

In preclinical studies, central nervous system (CNS) G-protein expression levels do not appear to change consistently as a result of antidepressant drug treatment. Gα~s~, Gα~o~ and Gα~i~ mRNA expression in the rat hippocampus remain constant following chronic treatment with the tricyclic antidepressant imipramine ([@B65]). However, levels of G-protein mRNA and protein expression do not always have a strong correlation ([@B63]), and so these results do not necessarily reflect the amount of G-protein present. Chronic treatment with the dual serotonin norepinephrine reuptake inhibitor (SNRI) amitriptyline, the tricyclic antidepressant desipramine, the MAOI tranylcypromine or electroconvulsive shock did not affect protein levels of Gα~s~, Gα~o~, Gα~i~ or Gβ in the rat cerebral cortex ([@B17]; [@B38]; [@B34]). In contrast, brief treatment with the MAOI antidepressant phenelzine increased Gα~i2~ protein expression in the rat cortex and hippocampus without affecting Gα~s~, Gα~o~, Gα~q~ or Gα~i1~ expression in any brain region ([@B34]). However, this does not appear to be a conserved effect for all MAOI antidepressants on Gα~i2~, as chronic treatment with tranylcypromine did not affect cortical Gα~i2~ expression while chronic clorgiline instead produced a small decrease ([@B68]; [@B38]). Three-week treatment with various tricyclic antidepressants (imipramine, desipramine, or chlomipramine) produced slight increases of brain Gα~o~ and decreases of Gα~s~ and Gα~i~, although the magnitude of these changes (∼10--30% from baseline) may not be great enough to produce functional consequences ([@B68]). Note that it has been suggested that Gα~s~ expression is over 30-fold higher than expression of downstream effectors ([@B91]), thus minor variations in the expression of Gα~s~ are not expected to influence downstream signaling. Furthermore, tricyclics such as desipramine and amitriptyline had no effect on G-protein expression ([@B17]; [@B38]).

On the other hand, a series of post-mortem studies examining the involvement of G-proteins in depressive states contrast with the findings from pre-clinical studies discussed above. Post-mortem studies indicate that a downregulation of Gα~o~ and Gα~i2~ protein and mRNA co-occurs with an upregulation of Gα~s~ protein levels and mRNA in the prefrontal cortex of adult suicide cases ([@B35]). This fits with data from Gα~i2~ knock-out mice which show that loss of Gα~i2~ contributes to depressive behaviors ([@B119]), suggesting that the observed alterations of Gα~i2~ in these subjects may have contributed to their pathology. However, the work of [@B28] shows only minor changes in Gα~s~ expression and none in other Gα proteins. Thus, there is no consistent effect on G-protein expression in the brain following chronic antidepressant treatment, the effects that have been seen are not consistent between antidepressant drugs with similar pharmacology, and any changes observed are of relatively small magnitude.

Effects on Gα~s~ Localization and Signaling
-------------------------------------------

Despite the lack of any clear effect on G-protein expression levels, chronic but not acute antidepressant drug treatment (including amitriptyline, desipramine and iprindole) increases cAMP concentrations in a Gα~s~ dependent manner in the rat brain, but not liver or kidney ([@B81]; [@B92]; [@B23]). In addition to antidepressant drug treatments, chronic electroconvulsive treatment increases coupling between Gα~s~ and adenylyl cyclase ([@B93]). Consistent with this increased adenylyl cyclase activity, increased activity of cAMP dependent kinases (e.g., Protein kinase A) have also been observed in the rat brain following chronic antidepressant treatment. These changes occurred with chronic but not acute treatment with desmethylimipramine, and were seen in the cerebral cortex but not hippocampus, striatum or cerebellum ([@B96]). This suggests a more general role for brain Gα~s~/adenylyl cyclase coupling in antidepressant action downstream of their better characterized direct effects on transporters and GPCRs.

In order to understand how antidepressant drugs affect G-protein signaling, it is necessary to consider not only the expression levels of these proteins and their binding partners, but also their subcellular localization in microdomains. Within the plasma membrane bilayer there are lipid raft microdomains which contain an increased proportion of both cholesterol and sphingomyelin ([@B110]) and the scaffolding protein Caveolin 1 (Figure [2](#F2){ref-type="fig"}). G-proteins are known to accumulate in these lipid raft domains, with Gα~s~, Gα~q,~ and Gα~i/o~ subunits all found at higher concentrations in these regions ([@B98]; [@B33]; [@B4]). These microdomains can affect G-protein mediated signaling, with either faciliatory or inhibitory effects on signaling depending on the G-protein. For example, localization to raft regions inhibits the ability of Gα~s~ proteins to increase cAMP levels through adenylyl cyclase activation ([@B3]), while raft localization of Gα~q~ greatly enhances signaling downstream of 5-HT2A receptor activation ([@B105]; [@B8]; [@B2] for review). In addition to an upregulation of Gα~s~ protein expression, a shift in Gα~s~ subcellular membrane localization also occurs in the brains of depressed humans. Thus, compared to non-psychiatric control subjects there was an approximately two-fold increase in the localization of Gα~s~ to lipid raft domains in both cerebral cortex and cerebellum from suicide cases with documented depression ([@B28]). As these lipid raft domains are known to inhibit signaling downstream of Gα~s~ ([@B105]; [@B82]; [@B49]; [@B3]), including coupling to adenylyl cyclase, this increased lipid raft localization likely indicates decreased Gα~s~ signaling in the depressed brain. In fact, a Gα~s~ dependent adenylyl cyclase dysfunction in the depressed brain is supported by impairment in the ability of forskolin to stimulate adenylyl cyclase activity in post-mortem tissue from individuals who completed suicide ([@B19]). This loss of adenylyl cyclase activity is associated with decreased expression and activity of the cAMP dependent kinase (PKA) in the frontal cortex, but not hippocampus of suicide completers ([@B94]).

![Antidepressant effects on Gα~s~ signaling. Antidepressant drugs (e.g., escitalopram, depicted) slowly accumulate in lipid raft domains **(1)**. These areas are defined in part by high cholesterol content, detergent insolubility, and expression of membrane proteins such as Caveolin-1. Antidepressant accumulation causes a translocation of Gα~s~ from lipid raft to non-raft membrane **(2)**, where coupling to downstream effectors such as adenylyl cyclase increases. This facilitates downstream signaling, including increased cAMP production **(3)**.](fphar-09-01289-g002){#F2}

Preclinical and *in vitro* models suggest that antidepressants cause both increased association of Gα~s~ with adenylyl cyclase (Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}) and reduce the relative amount of Gα~s~ localized in lipid rafts ([@B17],[@B18]; [@B123]; [@B29]; [@B3]; [@B130]; [@B111]; [@B129]). Both of these effects of antidepressants would in theory directly counteract changes detected in post-mortem brain tissue from suicide completers, namely impaired adenylyl cyclase activity and increased accumulation of Gα~s~ in lipid rafts ([@B19]; [@B28]). While these results predict that antidepressant treatment should correct these deficits observed in the depressed brain, this hypothesis has not yet been fully tested.

###### 

Antidepressants effects on Gα~s~ signaling.

                                 Gα~s~ Translocation   Gα~s~ Membrane mobility   cAMP   Reference
  ------------------------------ --------------------- ------------------------- ------ --------------------------------------------------------
  **Antidepressants**                                                                   
  Amitriptyline                  \+                                              \+     [@B81]; [@B92]; [@B17],[@B18]; [@B123]
  Bupropion                                            \+                               [@B21]
  Desipramine                    \+                    \+                        \+     [@B81]; [@B92]; [@B17],[@B18]; [@B123]; [@B29]; [@B21]
  Electroconvulsive Therapy                                                      \+     [@B81]; [@B93]; [@B17]
  Escitalopram                   \+                    \+                        \+     [@B130]; [@B21]; [@B30]; [@B39]; [@B111]
  Fluoxetine                     \+                    \+                               [@B123]; [@B29]; [@B21]
  Imipramine                     \+                    \+                        \+     [@B81]; [@B21]; [@B111]
  Iprindole                      \+                                              \+     [@B81]; [@B92]; [@B123]
  Phenelzine                                           \+                               [@B21]
  Sertraline                                           \+                               [@B21]
  Tianeptine                                           \+                               [@B21]
  Venlafaxine                                          \+                               [@B21]
  **Putative antidepressants**                                                          
  ABT 200                                                                        \+     [@B17]
  Ketamine                       \+                    \+                        \+     [@B129]
  Tubastatin-A                   \+                    \+                               [@B111]
  **Non-antidepressants**                                                               
  Amphetamine                                          \-                        \-     [@B17]
  Chlorpromazine                 \-                                                     [@B123]
  Diazepam                                             \-                               [@B21]
  Haloperidol                                          \-                               [@B21]
  Lithium                        \-                    \-                               [@B30]
  LY368514                       \-                                                     [@B30]
  Olanzapine                                           \-                               [@B21]
  R-citalopram                   \-                    \-                        \-     [@B130]; [@B21]
  Valproate                      \-                    \-                               [@B30]
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It is noteworthy, however, that recent PET imaging studies reveal decreased \[^11^C\]-Rolipram (a phosphodiesterase-4 inhibitor) binding in all brain regions of depressed subjects ([@B42]). Subsequent to successful antidepressant treatment \[^11^C\]-Rolipram binding returns to baseline throughout the CNS ([@B42]). This is consistent with the predictions from the work described above, as \[^11^C\]-Rolipram binding is known to reflect levels of cAMP ([@B55]), due to a feedback mechanism involving cAMP, PKA, and phosphodiesterase-4 ([@B57]).

In cellular models, multiple G-protein subtypes accumulate in lipid rafts and antidepressant drug treatment reduces the amount of lipid raft associated Gα~s~ without changing the abundance of other G-proteins in the rafts ([@B123]; [@B29]). This reduction in lipid raft Gα~s~ content occurs without changes in the overall expression level of Gα~s~ protein, or in the expression of other G-proteins including Gα~i~, Gα~o~ or Gβ ([@B18]). The shift of Gα~s~ from lipid raft regions to non-lipid raft regions coincides with increased coupling between Gα~s~ and adenylyl cyclase as well as increased adenylyl cyclase activation and cAMP accumulation (Table [1](#T1){ref-type="table"}; [@B17],[@B18]). Indeed, antidepressants including the tricyclic desipramine ([@B21]), the SSRI escitalopram ([@B39]), and the NMDA antagonist ketamine ([@B129]) reduce the lateral membrane mobility of Gα~s~ (Table [1](#T1){ref-type="table"}). This likely reflects increased association with the large, relatively immobile adenylyl cyclase protein following Gα~s~ translocation out of lipid raft domains ([@B21]). These effects occur with tricyclic antidepressants, SSRIs and atypical antidepressants, suggesting a potential conserved antidepressant mechanism independent of the known sites of action.

Importantly, the transfer of Gα~s~ out of lipid raft domains occurs following chronic treatment with the antidepressant (S)-stereoisomer of the SSRI citalopram, but not the (R)-stereoisomer which lacks antidepressant effects ([@B130]). This stereospecific effect of citalopram occurs in C6 cells lacking the serotonin transporter, suggesting that Gα~s~ translocation out of lipid rafts occurs due to interaction of the antidepressant with some other protein target. Furthermore, antidepressant drugs with diverse mechanisms of action (including desipramine, reboxetine and fluoxetine) themselves accumulate in these lipid raft domains over time ([@B37]). Initially these drugs distribute evenly throughout the plasma membrane, but gradually partition into lipid rafts over a 3-day treatment period ([@B39]). While together these data suggest that a specific binding site for antidepressants within lipid rafts may exist, a suitable candidate site has yet to be identified.

Therefore, in general antidepressant drugs liberate Gα~s~ from the inhibitory effects of lipid raft localization ([@B49]) allowing this subunit to signal more effectively through downstream effectors including adenylyl cyclase (Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). These effects are relatively specific to the brain as peripheral tissues do not show the same response, and even within the brain there is regional specificity as brain regions other than the cerebral cortex show reduced Gα~s~ translocation, if any ([@B35]). This provides a plausible mechanism for the long-recognized ability of antidepressant drugs to increase the coupling between Gα~s~ and adenylyl cyclase ([@B81]). This enhancement occurs only following extended antidepressant treatment, consistent with the hysteresis observed between the initiation of antidepressant treatment and the onset of therapeutic effects ([@B17]). Notably, ketamine, which is reported to have a rapid therapeutic onset, shows the antidepressant biosignature described above after only 15 min of treatment ([@B129]).

Although Gα~s~ coupling to adenylyl cyclase is unaffected by antidepressant treatment in peripheral tissues (e.g., liver and kidney; [@B81]), a variety of blood cells undergo changes similar to those observed in the brain. Lymphocytes and platelets from depressed subjects have diminished cAMP production due to decreased Gα~s~-adenylyl cyclase coupling ([@B52]) and this is resolved in subjects who respond to antidepressants ([@B95]; [@B84]). These data raise the possibility of using Gα~s~ signaling changes in peripheral blood cells to test for depression and antidepressant response, a strategy that has already seen some success with other markers detected in patient blood samples ([@B103]).

Together the above discussion suggests a dysregulation of G-protein signaling in the brains of depressed individuals. The dysregulation likely involves changes in overall G-protein expression, as well as translocation of Gα~s~ into a more restrictive membrane microenvironment where signaling to downstream effectors is inhibited, with apparent consequences for cyclase dependent signaling pathways including protein kinase A. It remains unclear whether these changes contribute to suicidal behavior and depression, or are simply correlated with the expression of these states without a causative effect. In either case the existence of these changes may allow for new strategies to diagnose and potentially treat depressive disorders.

RGS Proteins in Depression and Antidepressant Drug Action
=========================================================

As mentioned earlier RGS proteins are essential modulators of signaling downstream of the G-proteins discussed above. There are more than 20 members of the RGS protein family, designated by the presence of a 120 amino-acid RH domain and divided into subfamilies based on their structures outside of the RH domain ([@B56]; [@B126]). This variety indicates that RGS proteins have some degree of specificity for which Gα subunits they can regulate. For example, RGS4 and RGS8 potently inhibit signaling downstream of Gα~i2~ *in vitro* while RGS7 has no effect ([@B120]). RGS-PX1 and RGS-PX2 regulate signaling downstream of Gα~s~ ([@B131]; [@B46]), while RGS2 preferentially modulates Gα~q~ signaling ([@B50]). RGS proteins also appear to have specificity in terms of which GPCRs they modulate, even when those GPCRs signal through the same type of G-proteins. The dopamine D2 receptor and 5-HT1A receptors are both Gα~i/o~ coupled GPCRs, however, RGS4, RGS10 and RGSZ1 reduced 5-HT1A receptor-mediated signaling *in vitro* but did not affect D2-mediated signaling ([@B44]). It remains unclear whether RGS proteins achieve this specificity through direct interaction with certain GPCRs or by interactions with other intracellular binding partners.

Membrane anchoring can also affect how RGS proteins regulate G-protein action. For example, palmitoylation of RGS16 is necessary for regulation of Gα~i~ and Gα~q~ signaling ([@B53]). RGS proteins in complex with a Gα subunit can also directly affect signaling to downstream effectors, independent of their GAP function. This level of regulation also depends on the specific RGS protein involved, for instance RGS2 in complex with Gα~q~ can prevent Gα~q~ from binding to the downstream effectors p63 RhoGEF and GRK2, while RGS4 in complex with Gα~q~ has little effect on binding to these effectors ([@B107]).

Therefore, while different RGS proteins have classically been thought to have largely redundant actions, current evidence suggests that different family members might have considerable variation in G-protein preference, receptor selectivity, and scaffolding functions toward downstream effectors. This highlights the need for a better understanding of what role the RGS proteins play in neuropsychiatric disorders and treatments.

RGS Insensitive G-Proteins
==========================

When an individual RGS protein is knocked out or genetically modified, other available RGS proteins can at least partially compensate. Similarly, when an individual G-protein is lost, a GPCR may be able to continue signaling through other available G-proteins. In order to overcome these difficulties a series of modified G-proteins were developed which are insensitive to the negative regulatory effects of RGS proteins. These mutated G proteins have a Gly in the "switch 3" region of the Gα protein that binds RGS proteins, replaced with a Ser ([@B122]). This prevents the protein-protein interaction necessary for GAP activity.

The potential utility of RGS insensitive (RGSi) G-proteins was quickly recognized and a series of novel mammalian RGSi G-proteins were created ([@B25]; [@B64]). These mutations do not affect the kinetics of GDP release, GTP hydrolysis, Gβγ binding, or interaction with the receptor, but produce up to 100-fold loss of affinity for RGS proteins ([@B22]; [@B41]). These properties allowed investigators to probe the effects of removing all RGS control at a specific G-protein without affecting G-protein signaling otherwise, avoiding the difficulties posed by RGS protein redundancy.

Mice expressing an RGSi knock-in variant of Gα~i2~ display a profound antidepressant-like phenotype across a number of behavioral tests including tail suspension, forced swim, elevated plus maze and novelty induced hypophagia ([@B119]; [@B106]). These mice also have antidepressant-like signaling changes in the hippocampus and frontal cortex, including reduced glycogen synthase kinase 3 beta (GSK3β) activity ([@B119]). GSK3β inhibition produces neurogenesis in the adult hippocampus, and this neurogenic effect may be an important component of antidepressant action ([@B75]; [@B70]; [@B127]), although the significance of these antidepressant induced neurogenic effects has been disputed ([@B48]).

Both the changes in hippocampal GSK3β and antidepressant-like behaviors observed in RGSi Gα~i2~ knock-in mice are fully reversed by pretreatment with a 5-HT1A receptor antagonist ([@B119]). Furthermore, direct application of this 5-HT1A receptor antagonist to the hippocampus of the RGSi Gα~i2~ knock-in mice reversed their antidepressant-like behavior ([@B106]), suggesting that enhanced 5-HT1A receptor activity in the hippocampus is necessary for this behavior. Coupled with the fact that 5-HT1A receptor agonists produce more potent antidepressant-like effects in these animals, it appears that the loss of RGS control at Gα~i2~ promotes 5-HT1A receptor signaling leading to robust antidepressant-like effects. Mice heterozygous for RGSi Gα~o~ also show antidepressant-like effects in the tail suspension test, but the GPCR involved is not the 5-HT1A receptor and remains unidentified ([@B106]). The culprit in this case may be the delta opioid receptor (DOPR) since the potency of the delta agonist SNC80 to produce antidepressant-like effects is enhanced in these mice ([@B31]).

Although activating postsynaptic 5-HT1A heteroreceptors is generally considered beneficial for antidepressant action, presynaptic 5-HT1A autoreceptor activation can limit antidepressant action and may contribute to the hysteresis observed between initiation of treatment and the onset of therapeutic effects ([@B54]; [@B6]; [@B66]; [@B78]). Interestingly, RGSi Gα~i2~ knock-in mice display enhancements of responses known to depend on 5-HT1A heteroreceptor activity (e.g., antidepressant-like behaviors, hippocampal GSK3β inhibition), but not responses dependent on 5-HT1A autoreceptor activity (e.g., hypothermia; [@B51]; [@B78]; [@B70]; [@B119]). 5-HT1A receptor agonists also produce exaggerated responses in hippocampal neurons from these mice, with more robust 5-HT1A receptor dependent suppression of neuronal excitability observed in pyramidal neurons ([@B106]). As the hippocampus does not contain 5-HT cell bodies ([@B100]), this provides direct evidence for increased 5-HT1A heteroreceptor activity in these animals.

The above data suggest that disrupting RGS control of Gα~i2~ may represent a novel strategy to selectively enhance the antidepressant effects of 5-HT1A receptor activation without promoting the detrimental effects of autoreceptor activation. Unfortunately, specific RGS protein(s) responsible for the antidepressant-like phenotype in the RGSi-Gα~i2~ mice are not currently known, but two candidates (RGS6 and RGS19) are discussed later in this review.

Although the above studies highlight roles for RGS proteins in modulating depressive-like behaviors in preclinical models, they do not identify which RGS protein or proteins are involved. However, a limited number of studies have been performed on specific RGS proteins as described below.

RGS2
====

Mice lacking RGS2 showed a baseline increase in anxious and depressive-like behaviors ([@B90]; [@B71]). These behavioral alterations occur alongside decreased presynaptic 5-HT1A receptor expression and function, suggesting that these receptors may play a role in the observed behavioral phenotype ([@B71]; [@B85] for review). In contrast, a genetic manipulation which specifically increases raphe 5-HT1A receptor expression in mice increases vulnerability to stress and decreases response to antidepressants ([@B102]), suggesting that reductions in raphe 5-HT1A receptor availability following disruption of RGS2 may be a compensatory change rather than a causative factor of the pro-depressant behaviors. Nonetheless, these data demonstrate that RGS2 may have a protective effect against anxiety and depression, and that RGS2 disruption may have detrimental neuropsychiatric effects.

In line with these pre-clinical results, individuals expressing any of several single nucleotide polymorphisms (SNPs) in the RGS2 gene experience anxiety disorders and suicidal ideations at an increased rate ([@B69]; [@B112]; [@B5]). In addition, various RGS2 genetic variants were found at an increased rate in suicide completers than controls ([@B20]). However, an increase in RGS2 immunoreactivity was also found in post-mortem tissue from both the prefrontal cortex and amygdala of these subjects ([@B20]), although this may represent a compensatory upregulation due to a loss of RGS2 functionality. Together these findings provide solid evidence that genetic alterations in the RGS2 gene can influence the development or expression of affective disorders in human populations, in line with findings from RGS2 knockout mice.

While it remains difficult to study antidepressant action *in vitro*, a number of reports have provided evidence on how RGS2 can affect cellular processes in ways that might modify antidepressant action. For example, an increase in hippocampal synaptic plasticity typically occurs following antidepressant treatment, while depressive states cause decreased plasticity ([@B62]; [@B88]). Loss of RGS2 produces a similar loss of synaptic plasticity in mouse hippocampal tissue potentially by altering Gα~i/o~-mediated inhibition of hippocampal Ca^2+^ channels ([@B47]). This suggests that a loss of neural plasticity due to genetic variation in RGS2 could have detrimental neuropsychiatric effects and might impair the function of antidepressant drugs.

RGS4
====

Studies in rodent models have consistently shown that 5-HT1A receptor agonists such as 8-OH-DPAT cause a reduction in extracellular serotonin levels in the brain by activating 5-HT1A autoreceptors in the dorsal raphe nucleus ([@B15]; [@B1]; [@B16]). It is thought that this 5-HT1A receptor-dependent reduction in central serotonin may delay the beneficial effects of SSRI antidepressants. Indeed, strategies to limit 5-HT1A autoreceptor activity during SSRI treatment, such as co-administration of 5-HT1A receptor antagonists or weak partial agonists, have shown promising results ([@B6]; [@B97]; [@B124]; [@B74]). Although RGS4 mRNA is not normally expressed in the dorsal raphe nucleus ([@B45]), RGS4 overexpression in this region attenuates the ability of 5-HT1A receptors to reduce central serotonin levels ([@B7]). Based on these results, overexpression or stimulation of RGS4 in brain regions containing 5-HT1A autoreceptors should have beneficial effects on antidepressant drug action, similar to the results obtained by combining 5-HT1A antagonists with traditional antidepressants ([@B6]).

Delta opioid receptor agonists produce antidepressant-like behavioral effects in rodent models including the tail suspension and forced swim tests ([@B13]; [@B86]). RGS4 knockout mice show an enhanced antidepressant-like response to DOPR agonists in the forced swim test, but not tail suspension test, suggesting that these antidepressant-like behaviors may depend on distinct neural pathways or signaling intermediates downstream of DOPR activation ([@B116]; [@B32]). This effect on forced swim test behavior appears to depend on nucleus accumbens RGS4 expression, as specific RGS4 knockdown in this region produces similar effects as global RGS4 knockout ([@B116]). RGS proteins capable of modulating DOPR-mediated tail suspension test behavior have not yet been identified.

In addition to inhibiting the antidepressant-like effects of DOPR agonists, loss of RGS4 appears to inhibit the antidepressant-like effects of SSRIs, norepinephrine reuptake inhibitors and the *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptor antagonist ketamine ([@B116]). Acute treatment with either a DOPR agonist or ketamine decreases frontal cortex RGS4 expression yet only chronic treatment with a DOPR agonist increases RGS4 expression in the nucleus accumbens ([@B116]). While this would suggest that nucleus accumbens and frontal cortex RGS4 have opposing effects on antidepressant action, this has yet to be conclusively demonstrated. Although RGS4 expression in the brain does not appear to differ between post-mortem tissue from depressed and healthy individuals, an upregulation of RGS4 has been observed in post-mortem nucleus accumbens tissue from depressed individuals undergoing antidepressant treatment compared to untreated depressed individuals ([@B116]). Coupled with findings from rodent models showing increased antidepressant effectiveness in animals with overexpression of RGS4 in this brain region, it appears possible that nucleus accumbens RGS4 has a facilitatory effect on antidepressant treatment.

The RGS4 inhibitor CCG-203769 produces antidepressant-like effects on the tail suspension test in a mouse model ([@B106]). As RGS4 knockout mice do not have behavioral changes on the tail suspension test ([@B32]), and loss of RGS4 inhibits the antidepressant-like effects of drugs with diverse mechanisms of action ([@B116]), RGS4 inhibition alone cannot explain the antidepressant-like effect of CCG-203769. However, CCG-203769 also inhibits RGS19, and downregulation of RGS19 has been shown to increase 5-HT1A receptor signaling in hippocampal neurons ([@B128]). CCCG-203769's antidepressant-like effects are discussed in more detail in the section on RGS19.

RGS6
====

Mice lacking RGS6 display antidepressant-like and anxiolytic behaviors at baseline, including in the elevated plus maze and novelty induced hyponeophagia test ([@B113]). This behavioral phenotype is fully reversible by 5-HT1A receptor antagonist pretreatment, and by direct activation of adenylyl cyclase with forskolin ([@B113]). Loss of RGS6 did not affect mitogen-activated protein kinase (MAPK) or GSK3β signaling ([@B113]), changes that have been detected in mice with a 5-HT1A receptor dependent antidepressant-like phenotype due to loss of RGS control at Gα~i2~ ([@B119]). Instead the RGS6 knockout mouse phenotype appears to depend on increased phospho-CREB in the hippocampus and cortex, areas with high 5-HT1A receptor expression ([@B113]). The mechanistic differences across the two mouse models calls into question whether RGS6 is the primary mediator of the RGSi-Gα~i2~ knock-in mouse behavioral phenotype, although it may be one of several RGS proteins involved. Nonetheless, the findings suggest that RGS6 may normally limit the actions of serotonergic antidepressants by reducing adenylyl cyclase inhibition downstream of 5-HT1A receptor activation, and that strategies to limit RGS6 activity may have beneficial effects for antidepressant treatment.

RGS8
====

Overexpression of RGS8 in mouse brain produces an antidepressant-like behavioral phenotype in the forced swim test ([@B61]). RGS8 is a potent negative modulator of melanin-concentrating hormone receptor 1 (MCHR1) signaling ([@B83]). Inhibitors of MCHR1 have antidepressant-like effects, however, this action is lost in mice overexpressing RGS8, suggesting signaling downstream of MCHR1 is the target for RGS8. Whether loss of central RGS8 produces a pro-depressant phenotype has not yet been tested, although small molecule compounds with inhibitory action against RGS8 ([@B10]; [@B115]) could provide the means to examine these behaviors in future studies. While these RGS8 inhibitors are not highly potent or selective, a detailed analysis of the binding sites for these inhibitors ([@B108]) will facilitate the discovery of more selective compounds.

RGS16
=====

Although RGS16 has not been directly linked to depression, palmitoylation causes the accumulation of RGS16 in lipid raft domains, a subcellular membrane compartment known to generally promote signaling downstream of Gα~q.~ ([@B105]; [@B53]). As discussed earlier, this localization places RGS16 at or near the putative, but not yet positively identified, binding site for antidepressant drugs within lipid rafts ([@B37]; [@B39]). This localization may provide RGS16 with an increased ability to regulate antidepressant drug action, although this prediction has yet to be tested.

RGS17 (RGSZ2)
=============

Levels of RGS17 mRNA (also known as RGSZ2) were shown to be markedly reduced in post-mortem brain tissue from individuals diagnosed with MDD ([@B109]) in a large-scale RNA microarray analysis. Unfortunately, this study did not provide a potential mechanism by which MDD affects RGS17, nor evidence that these changes in RGS17 mRNA reflect changes in RGS17 activity.

RGS19 (Gaip)
============

RGS19, also known as G Alpha Interacting Protein (GAIP; [@B24]) has been shown to regulate 5-HT1A receptor signaling in both C6 and SH-SY5Y cells ([@B128]). RGS19 knockdown facilitated 5-HT1A receptor agonist induced activation of MAPK and inhibition of adenylyl cyclase ([@B128]), while RGS4 knockdown did not significantly affect signaling. The effect of RGS19 knockdown was magnified when the cells were co-treated with fibroblast growth factor 2 (FGF2), a factor known to act synergistically with 5-HT1A receptor activity in the hippocampus to facilitate synaptic plasticity ([@B12]; [@B128]). The enhancement of 5-HT1A receptor agonist stimulated MAPK activity following RGS19 knockdown seen in cellular models was replicated in mouse primary hippocampal neurons, including the synergistic enhancement by co-treatment with FGF2 and a 5-HT1A receptor agonist ([@B128]). This suggests that reducing RGS19 activity may facilitate the action of serotonergic antidepressants due to disinhibition of hippocampal 5-HT1A receptor activity.

CCG-203769, an RGS inhibitor with 100-fold selectivity for RGS19 and RGS4 compared to other RGS proteins ([@B9]), produces antidepressant-like effects in a mouse model ([@B106]). These effects occur after repeated intra-hippocampal administration in female, but not male mice ([@B106]), suggesting that behavioral responses to RGS inhibitors may be sexually dimorphic. This behavioral sex difference occurs despite similar hippocampal expression of RGS19 between male and female mice ([@B106]).

As discussed above, loss of RGS4 activity attenuates the effects of various antidepressants ([@B116]), suggesting that the antidepressant-like behavioral effects observed following CCG-203769 administration are not likely to be mediated by its inhibitory effect on RGS4 ([@B9]; [@B106]). In contrast, loss of RGS19 activity facilitates 5-HT1A receptor mediated MAPK activity ([@B128]), signaling changes that have been associated with antidepressant-like behaviors in animal models ([@B119]). While not conclusive, these data suggest that the antidepressant-like effects of CCG-203769 in female mice are due to its inhibitory effects on RGS19 ([@B106]). This is the first report of antidepressant-like behaviors produced by a compound which targets RGS proteins directly, although the requirement for central delivery of CCG-203769, and its action as an irreversible inhibitor, suggests that novel RGS inhibitors with improved drug-like properties are needed before this class of compounds can be fully explored for potential clinical utility.

RGS20 (RGSZ1)
=============

In post-mortem tissue from individuals with MDD, RGS20 (also known as RGSZ1) mRNA is significantly decreased in the anterior cingulate cortex ([@B125]). This change was not observed in tissue from individuals with bipolar disorder ([@B125]). It remains unclear whether this change in RGS20 mRNA is reflected by changes in protein expression or activity. Furthermore, as the majority of these individuals were undergoing neuropsychiatric treatment at time of death, it is impossible to determine whether RGS20 mRNA was reduced due to antidepressant treatment, or reflects an innate difference in the depressed brain.

Chronic estradiol treatments both desensitize hypothalamic 5-HT1A receptors and cause an increase in plasma membrane RGS20 expression ([@B14]; [@B80]). Increased RGS20 is predicted to reduce signaling downstream of 5-HT1A receptor and therefore may contribute to the observed 5-HT1A receptor desensitization, although this interaction has not been conclusively demonstrated ([@B14]). 5-HT1A receptor desensitization in the dorsal raphe nucleus, not the hypothalamus, is generally considered a critical step in antidepressant action. However, RGS20 expression in the dorsal raphe has not been assessed following chronic antidepressant treatment, so it remains possible that a similar process contributes to 5-HT1A receptor desensitization in this brain region.

Conclusion
==========

G-proteins and their RGS protein modulators likely play important roles in the development of depressive states, and also influence the effectiveness of antidepressant therapies. Changes in activity of these proteins can have dramatic effects on these complex disorders, while even more subtle alterations, such as G-protein translocation between subcellular microdomains, can profoundly regulate antidepressant action. Although preclinical studies provide multiple hypotheses for how these proteins behave in depressed populations in the clinic, only a handful of these theories have been addressed in humans. Considering how alterations in G-proteins and/or RGS differentially affect responses to a variety of antidepressant treatments, it appears reasonable that a better understanding of these proteins could aid in the tailoring of personalized treatment strategies for depression. Screening for changes in G-protein signaling pathways could also provide new insight into susceptibility toward depressive disorders at an individual level. In addition, direct RGS-inhibiting compounds have been proposed as novel treatment options for a variety of indications, and selective small molecule RGS inhibitors have already been identified ([@B132]; [@B104]; [@B108]). A more complete understanding of how these G-proteins and their partners interact with antidepressant therapies and the development of depressive states is both needed and welcome.

Author Contributions
====================

NS provided the original draft, and editing of subsequent drafts. MR and JT provided project funding, and manuscript review and editing.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** NS was supported by T32 GM 007767 and VA BX001149; JRT by R01 DA 035316. MR is supported by R01 AT009169 and VA BX001149.

[^1]: Edited by: Hector J. Caruncho, University of Victoria, Canada

[^2]: Reviewed by: Dasiel Oscar Borroto-Escuela, Karolinska Institute (KI), Sweden; Nasiara Karim, University of Malakand, Pakistan

[^3]: This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
